Get the Stockscreener App
0.37
0.27%
-0.001
Collplant Biotechnologies Ltd stock is traded at $0.37, with a volume of 20,416.
It is down -0.27% in the last 24 hours and down -8.01% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$0.371
Open:
$0.38
24h Volume:
20,416
Relative Volume:
0.26
Market Cap:
$5.34M
Revenue:
$2.37M
Net Income/Loss:
$-11.49M
P/E Ratio:
-0.3962
EPS:
-0.9338
Net Cash Flow:
$-10.02M
1W Performance:
-7.73%
1M Performance:
-8.01%
6M Performance:
-81.86%
1Y Performance:
-80.93%
1-Day Range:
$0.37
$0.38
1-Week Range:
$0.37
$0.42
52-Week Range:
$0.2711
$3.2324
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.37 | 5.35M | 2.37M | -11.49M | -10.02M | -0.9338 |
VRTX
Vertex Pharmaceuticals Inc
|
442.96 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.34 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.41 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.16 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.49 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents - Bez Kabli
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Sahm
CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline - The Globe and Mail
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Benzinga
CollPlant (CLGN) Reports Q1 2026 Financials and Strategic Updates - GuruFocus
CollPlant Q1 revenue falls to $73K, initiates strategic review - grafa.com
Collplant Biotechnologies: No Definitive Timetable for Process >CLGN - Moomoo
Collplant Biotechnologies: Initiates Process to Evaluate Strategic Alternatives Aimed at Maximizing Shareholder Value >CLGN - Moomoo
Collplant Biotechnologies 1Q Loss $3.1M >CLGN - Moomoo
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Quantisnow
CLGN Q4 2025 Earnings: Miss on EPS as Pre-Revenue Biotech Advances PipelineViral Trade Signals - Newser
CLGN Q1'26 Earnings: revenue estimate is 460.00K USD - TradingView
TradingKey - TradingKey
D. Boral Capital Maintains CollPlant Biotechnologies (CLGN) Buy Recommendation - MSN
CLGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Hugh M. Evans (CLGN) details CollPlant share, RSU and option holdings - Stock Titan
[EFFECT] CollPlant Biotechnologies Ltd SEC Filing - Stock Titan
CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares - Stock Titan
CollPlant (CLGN) Stock: Investment Potential Insight (Climbs) 2026-04-20Social Buzz Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Jasmine Seror Net Worth (2026) - GuruFocus
Avraham Havron Net Worth (2026) - GuruFocus
Elan Penn Net Worth (2026) - GuruFocus
Bowman Bagley Net Worth (2026) - GuruFocus
Bar Berta Abelis Net Worth (2026) - GuruFocus
Eran Rotem Net Worth (2026) - GuruFocus
Oren Fahimipoor Net Worth (2026) - GuruFocus
Philippe Bensimon Net Worth (2026) - GuruFocus
Yehiel Tal Net Worth (2026) - GuruFocus
CollPlant (NASDAQ: CLGN) registers 3.296M resale shares; warrants detail - Stock Titan
CLGN SEC FilingsCollplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Momentum Shift: Can CollPlant Biotechnologies Ltd sustain earnings growthGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
CollPlant implementing cost-reduction and workforce optimization plan - TipRanks
CLGN Implements Major Cost-Cutting Measures for Future Growth - GuruFocus
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead - Intellectia AI
CollPlant Resets Strategy After AbbVie Ends Filler Deal, Slashes Workforce by 50% - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% By Investing.com - Investing.com South Africa
CollPlant announces termination of development agreement with AbbVie - TipRanks
AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50% - Stock Titan
CollPlant Biotechnologies Ltd and Allergan Industrie SAS Terminate Development Agreement - marketscreener.com
CollPlant Issues Letter to Shareholders (2026-04-13) - Seeking Alpha
Is CollPlant (CLGN) Stock Leading the Market | Price at $0.34, Down 10.99%Profitability Factor - The Legal Advocate
Buyback Watch: Does CollPlant Biotechnologies Ltd stock have upside surprise potentialCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Is CollPlant (CLGN) Stock in a Selling Zone | Price at $0.41, Up 6.77%Revenue Weighted - The Legal Advocate
Aug Swings: What is CollPlant Biotechnologies Ltds debt to equity ratioEarnings Recap Summary & High Return Trade Guides - baoquankhu1.vn
Will CollPlant (CLGN) Stock Outperform S&P 500 | Price at $0.50, Down 5.48%Flat Correction - The Legal Advocate
CLGN Stock Analysis: CollPlant Biotechnologies 0.53 Daily Dip Performance Update - The Legal Advocate
CollPlant Files to Sell 3.3M Ordinary Shares - Intellectia AI
CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale - Stock Titan
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):